Skip to main content

Table 2 Clinical, functional, and laboratory data at baseline and at 3 and 6 months of treatment

From: Real-life experience with benralizumab during 6 months

Variables

BaselineMean (SD)

3 months Mean (SD)

6 months Mean (SD)

p*

ACT

13.9 (4.1)

20.1 (3.7)

21 (2.7)

< 0.001

Patients with controlled asthma (ACT≥20)

2 (4.8)

24 (57.1)

34 (81)

< 0.001

No. of ED visits per quarter, median (interquartile range)

1 (IR:0.7)

0 (IR:0.75)

0 (IR:0)

< 0.001

Corticosteroid-dependent, n (%)

16 (40%)

15 (35.7%)

8 (19%)

0.008

Inhaled budesonide (or equivalent) dose, ÎĽg/day

956 (475)

802 (415)

714 (356)

0.001

Oral prednisone dose, mg/day

19.6 (9)

7.5 (8.6)

5 (7.9)

0.007

Cycles of OCS per quarter, median (interquartile range)

1.5 (IR:1.25)

0 (IR:1)

0 (IR:0)

< 0.001

FEV1 mL

1429.4 (475)

1680 (481)

1721 (610)

< 0.001

FEV1%

64.3 (9.3)

73.1 (9.1)

76 (12)

< 0.001

FeNO

61.5 (23.9)

30.6 (14.6)

27.8 (14.9)

< 0.001

Blood eosinophil count, cells/ÎĽL

757.2 (278)

18.9 (18)

15.2 (13.6)

< 0.001

  1. * Comparison between data at baseline and at 6 months
  2. Abbreviations: ACT Asthma Control Test, BD Bronchodilator, BMI Body mass index, ED Emergency department, FeNO Fractional exhaled nitric oxide, FEV1 Forced expiratory volume in 1 s, OCS Oral corticosteroids, SD Standard deviation